By: RS Abdi Waluyo
It often starts with a routine blood test. Your PSA comes back higher than expected, and your doctor recommends a prostate MRI. The report describes “a suspicious lesion” and assigns it a score: PI-RADS 4.
The question that follows is almost always the same: “Does this mean I have prostate cancer?”
Not necessarily. MRI is very good at showing where something looks abnormal, but it cannot by itself confirm what that area is. A definitive diagnosis generally requires examining a small sample of tissue under a microscope. MRI fusion prostate biopsy is a way of taking that sample from precisely the area your MRI has flagged.
PSA: An Important Signal, Not a Diagnosis
PSA (prostate-specific antigen) is a protein made by prostate tissue, both healthy and abnormal, and measured with a simple blood test.
An elevated PSA tells your doctor that something in the prostate deserves a closer look. It does not say what that something is. Common causes include:
- Benign prostate enlargement (BPH), which becomes very common with age
- Inflammation of the prostate (prostatitis) or a urinary tract infection
- Recent procedures involving the bladder or prostate, such as catheterisation or cystoscopy
- Prostate cancer
This is why prostate cancer is never diagnosed on PSA alone. Doctors often repeat the test and interpret it alongside your age, prostate size, PSA density (PSA relative to prostate volume), physical examination, family history, and any previous biopsies.
What Prostate MRI Adds
Multiparametric prostate MRI (mpMRI) combines several types of MRI image, each highlighting a different property of the tissue, such as its anatomy and how tightly packed its cells are. Together, they help the radiologist spot areas that behave differently from the surrounding prostate.
This gives your care team two valuable pieces of information: whether there is a suspicious area, and exactly where it is. That location becomes the basis for planning a biopsy.
Radiologists report prostate MRI findings using PI-RADS (Prostate Imaging–Reporting and Data System), a 1-to-5 scale describing how likely it is that clinically significant prostate cancer is present:
- PI-RADS 1: very low suspicion
- PI-RADS 2: low suspicion
- PI-RADS 3: intermediate, or equivocal
- PI-RADS 4: high suspicion
- PI-RADS 5: very high suspicion
One point is worth stressing: PI-RADS is an imaging assessment of suspicion. It is not a cancer stage, and it is not a diagnosis. Your urologist will always interpret it together with PSA, PSA density, examination findings, family history, age, and other risk factors. Equally, a reassuring MRI does not completely rule out cancer, so some men still need follow-up based on their overall risk.
What is “clinically significant” prostate cancer? Broadly, it refers to cancer with features that make it more likely to need treatment or close medical attention, as opposed to very low-risk disease that can often be safely monitored.
If the MRI Can See It, Why Is a Biopsy Still Needed?
This is one of the most important questions patients ask, and the answer comes down to two different kinds of evidence.
MRI provides imaging evidence. It shows that an area looks different and how suspicious it appears. But some benign conditions, such as inflammation or BPH nodules, can occasionally look similar to cancer on a scan.
A biopsy provides histopathological evidence: a pathologist examines the tissue itself under a microscope. This can show:
- Whether cancer cells are actually present
- How aggressive the cells appear, expressed as a Gleason score and Grade Group (from 1 to 5)
- How much of each sample is involved
Those details shape everything that follows, including whether monitoring or treatment is the better path.
Put simply: MRI shows your doctor where to look. A biopsy tells your doctor what is actually there.
What Is MRI Fusion Prostate Biopsy?
MRI fusion prostate biopsy is a targeted biopsy in which your earlier prostate MRI is digitally aligned, or “fused”, with live ultrasound images during the procedure.
Think of the MRI as a detailed map with the destination clearly marked. During the biopsy, ultrasound works like a live camera, showing the prostate and the biopsy needle in real time. Fusion technology lines up the map with the camera view, so the urologist can steer the needle towards the area marked on MRI.
Why combine them? Ultrasound alone often cannot distinguish the suspicious area that MRI shows clearly. MRI, in turn, offers rich detail but is not taken live as the needle moves. Fusion brings together the strengths of both.
Step by step:
- You have a prostate MRI.
- The radiologist identifies and outlines any suspicious area.
- During the biopsy, the prostate is imaged with real-time ultrasound.
- Software aligns the MRI information with the ultrasound, so the MRI target appears on the ultrasound screen.
- The urologist uses this combined view to guide the needle and take several samples from the target.
- When clinically appropriate, additional samples may be taken from tissue immediately around the target (perilesional sampling) or systematically from other parts of the prostate.
It helps to know that the prostate can shift or change shape slightly between the MRI and the biopsy, so alignment accuracy depends on MRI quality, equipment, and team experience. Software fusion is one of several targeting methods; others include cognitive fusion, where the urologist matches the MRI to the ultrasound visually, and in-bore biopsy performed inside the MRI scanner.
MRI Fusion Biopsy and Systematic Biopsy Compared
| Feature | Systematic (Conventional) Biopsy | MRI Fusion (Targeted) Biopsy |
| How sample sites are chosen | A standard pattern covering different regions of the prostate | Directed at suspicious areas seen on MRI |
| Use of MRI information | MRI not required | MRI used as the guiding map |
| Sampling an MRI-visible lesion | May sample it, but does not aim at it specifically | Aims at it specifically |
| Sampling strategy | Cores spread evenly across the gland | Several cores from each target, often combined with perilesional or systematic cores |
| Clinical role | Still valuable, e.g. when MRI shows no lesion but clinical risk remains, or alongside targeted cores | Particularly valuable when MRI identifies a suspicious area |
These approaches are complementary, not competing. Systematic biopsy is not obsolete, and targeted biopsy does not automatically replace it. Current international guidelines support combining strategies, and the right mix depends on each patient’s situation.
Who May Be Considered for MRI Fusion Prostate Biopsy?
Every biopsy decision is individual. Not every raised PSA needs a biopsy, and not every MRI finding must be sampled. MRI fusion biopsy may be considered for men who have:
- A suspicious area on prostate MRI (typically PI-RADS 4 or 5, and in some cases PI-RADS 3 with additional risk factors)
- An elevated or steadily rising PSA with clinical concern
- A high PSA density or other risk factors
- A previous negative biopsy but ongoing suspicion, with a suspicious area on MRI
- Other situations in which the urologist judges a targeted tissue diagnosis to be appropriate
Your urologist will weigh the benefits and risks with you, taking into account your age, general health, and personal preferences.
What Happens During the Procedure?
Preparation. Your doctor will review your medical history and medications, particularly blood thinners (anticoagulants) and antiplatelet drugs such as aspirin. Never stop a medication on your own; any adjustment should follow your doctor’s advice. Your infection risk will also be assessed, for example with a urine test, and preventive antibiotics given according to protocol.
Biopsy route. A prostate biopsy can be performed through the skin of the perineum, the area between the scrotum and the anus (transperineal), or through the rectum (transrectal). Several guidelines, including those of the EAU, favour the transperineal route because it is associated with a lower risk of infection. The technique used depends on the facility, equipment, your urologist’s assessment, and your clinical situation.
Anaesthesia. Depending on the technique, the procedure may be performed under local anaesthesia, sedation, or general anaesthesia. Some men still notice brief pressure or discomfort.
During the biopsy. An ultrasound probe images the prostate, the MRI is fused with the live ultrasound, and the urologist takes several small tissue samples from the target. Additional samples may be taken where needed.
Recovery. You will be observed for a short time afterwards. Many patients go home the same day, depending on the medical team’s assessment.
After the Biopsy: What Is Normal and When to Seek Help
Some mild, temporary effects are common:
- Blood in the urine for a few days
- Blood in the semen, which can last several weeks and is usually harmless
- A small amount of blood in the stool, particularly after a transrectal biopsy
- Mild soreness or bruising around the perineum
Contact your doctor promptly or go to the emergency department if you experience:
- Fever or chills
- Inability to pass urine
- Heavy or persistent bleeding, or passing blood clots
- Pain that is severe or getting worse
- Other signs of infection, such as feeling very unwell or severe burning when passing urine
Follow the aftercare instructions from your own doctor, including advice on medications and returning to normal activities.
What If the Biopsy Shows Cancer?
A diagnosis is not the end of the evaluation; it is the starting point for a more informed plan.
Your care team will combine the pathology result (including Gleason score and Grade Group) with your PSA, MRI findings, clinical stage, general health, and other factors to determine your risk group. Some men will need further imaging.
Management options vary widely. For selected low-risk cancers, active surveillance, a structured programme of regular monitoring, may be appropriate. Other options can include focal therapy in carefully selected patients, surgery to remove the prostate, radiotherapy, or a combination of treatments. No single option is right for everyone, and decisions are made together with you.
Comprehensive Prostate Evaluation at RS Abdi Waluyo
Assessing possible prostate cancer works best as one connected pathway rather than a series of separate tests. RS Abdi Waluyo offers Urology services and Radiology services, including 3 Tesla MRI, supporting a pathway that brings each step together:
- Consultation with a urologist
- PSA testing and risk assessment
- Prostate MRI when indicated
- Review of any suspicious MRI findings
- Targeted prostate biopsy when clinically indicated
- Pathology evaluation
- Individualised treatment planning
An integrated pathway means every decision, from whether you need an MRI to whether you need a biopsy, is made with the full picture in view.
FAQ
- Does a high PSA mean I have prostate cancer? Not necessarily. PSA can rise because of benign enlargement, inflammation, infection, recent procedures, or cancer. It is one part of the assessment, not a diagnosis.
- What do PI-RADS 3, 4, and 5 mean? PI-RADS describes the level of suspicion on MRI. PI-RADS 3 is equivocal, PI-RADS 4 indicates high suspicion, and PI-RADS 5 very high suspicion for clinically significant prostate cancer.
- Is PI-RADS 4 or 5 always cancer? No. The likelihood is higher than with lower scores, but PI-RADS is neither a diagnosis nor a cancer stage. Only examination of tissue can confirm cancer.
- I have already had an MRI. Why do I still need a biopsy? MRI shows where a suspicious area is and how suspicious it looks. A biopsy confirms whether cancer is present and how aggressive it is, which is essential for planning care.
- How is MRI fusion biopsy different from a standard prostate biopsy? A systematic biopsy samples the prostate in a standard pattern. An MRI fusion biopsy uses the MRI as a map to aim at the suspicious area. The two are often combined, depending on your situation.
- Is MRI fusion prostate biopsy painful? The procedure is performed under local anaesthesia, sedation, or general anaesthesia. Some men feel brief pressure or discomfort, and any soreness afterwards is usually mild and temporary.
- Is a prostate biopsy risky? It is a common, well-established procedure, but it does carry risks such as bleeding, infection, and difficulty passing urine. Your urologist will explain these risks and how they are minimised before the procedure.
- How long do prostate biopsy results take? This varies with each hospital’s pathology process and whether additional tests are needed. Your care team can give you an estimate.
If you have an elevated PSA, an abnormal prostate examination, or a suspicious finding on prostate MRI, a consultation with a urologist can help clarify whether further evaluation or a prostate biopsy is needed. The Urology and Radiology teams at RS Abdi Waluyo in Jakarta are here to guide you through each step. To learn more or book a consultation, visit www.abdiwaluyo.com.
References
- EAU – EANM – ESTRO – ESUR – ISUP – SIOG Guidelines on Prostate Cancer. European Association of Urology, 2026 edition. uroweb.org/guidelines/prostate-cancer
- Early Detection of Prostate Cancer: AUA/SUO Guideline (2023, amended 2026). American Urological Association / Society of Urologic Oncology. J Urol. auanet.org
- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection, current version. National Comprehensive Cancer Network. nccn.org
- Turkbey B, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update. Eur Urol. 2019;76(3):340–351.
- Kasivisvanathan V, et al. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (PRECISION). N Engl J Med. 2018;378(19):1767–1777.
- Ahdoot M, et al. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med. 2020;382(10):917–928.
- Drost FJH, et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database Syst Rev. 2019;4:CD012663.
